Pronota and Molecuence announce collaboration in protein biomarker discovery
23-Feb-2011
- Belgium
Pronota NV announced that it has entered into an agreement with Molecuence Corporation, a wholly owned subsidiary of Mitsubishi Chemical Corporation, to discover and validate protein biomarkers in stroke. Pronota will apply its proprietary platforms for protein biomarker discovery (MASStermind®) and biomarker verification (MASSterclass™) to this project. The financial terms have not been disclosed.
“We’re finding potential collaborators are increasingly persuaded by our track record of not only being able to identify novel protein biomarkers, but also of taking these successfully through the verification process to show they are true, robust and clinically relevant discoveries. We’re delighted to be working with Molecuence, who are one of the leaders in the field of protein biomarker development for diagnostic applications”, commented Nick McCooke, CEO of Pronota.
Most read news
Other news from the department business & finance

Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.